Literature DB >> 26908609

Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency.

María Collantes1, Irantzu Serrano-Mendioroz2, Marina Benito3, Francisco Molinet-Dronda4, Mercedes Delgado5, María Vinaixa6, Ana Sampedro2, Rafael Enríquez de Salamanca7, Elena Prieto8, Miguel A Pozo5, Iván Peñuelas1, Fernando J Corrales9, Miguel Barajas10, Antonio Fontanellas11.   

Abstract

Porphobilinogen deaminase (PBGD) haploinsufficiency (acute intermittent porphyria, AIP) is characterized by neurovisceral attacks when hepatic heme synthesis is activated by endogenous or environmental factors including fasting. While the molecular mechanisms underlying the nutritional regulation of hepatic heme synthesis have been described, glucose homeostasis during fasting is poorly understood in porphyria. Our study aimed to analyse glucose homeostasis and hepatic carbohydrate metabolism during fasting in PBGD-deficient mice. To determine the contribution of hepatic PBGD deficiency to carbohydrate metabolism, AIP mice injected with a PBGD-liver gene delivery vector were included. After a 14 h fasting period, serum and liver metabolomics analyses showed that wild-type mice stimulated hepatic glycogen degradation to maintain glucose homeostasis while AIP livers activated gluconeogenesis and ketogenesis due to their inability to use stored glycogen. The serum of fasted AIP mice showed increased concentrations of insulin and reduced glucagon levels. Specific over-expression of the PBGD protein in the liver tended to normalize circulating insulin and glucagon levels, stimulated hepatic glycogen catabolism and blocked ketone body production. Reduced glucose uptake was observed in the primary somatosensorial brain cortex of fasted AIP mice, which could be reversed by PBGD-liver gene delivery. In conclusion, AIP mice showed a different response to fasting as measured by altered carbohydrate metabolism in the liver and modified glucose consumption in the brain cortex. Glucose homeostasis in fasted AIP mice was efficiently normalized after restoration of PBGD gene expression in the liver.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26908609     DOI: 10.1093/hmg/ddw013

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  11 in total

Review 1.  Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.

Authors:  Makiko Yasuda; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2019-01-18       Impact factor: 4.797

2.  An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia.

Authors:  Federica Depetri; Massimo Cugno; Giovanna Graziadei; Elena Di Pierro; Francesca Granata; Flora Peyvandi; Maria Domenica Cappellini
Journal:  Intern Emerg Med       Date:  2018-03-17       Impact factor: 3.397

Review 3.  Hepatic porphyria: A narrative review.

Authors:  Sumant Arora; Steven Young; Sudha Kodali; Ashwani K Singal
Journal:  Indian J Gastroenterol       Date:  2016-10-31

4.  Characterization of the hepatic transcriptome following phenobarbital induction in mice with AIP.

Authors:  Brenden Chen; Minghui Wang; Lin Gan; Bin Zhang; Robert J Desnick; Makiko Yasuda
Journal:  Mol Genet Metab       Date:  2019-01-06       Impact factor: 4.797

Review 5.  Nutrients and Porphyria: An Intriguing Crosstalk.

Authors:  Elena Di Pierro; Francesca Granata
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

6.  Diagnosis of acute intermittent porphyria in a renal transplant patient: A case report.

Authors:  Cristina Sirch; Niloufar Khanna; Lynda Frassetto; Francesco Bianco; Mary Louise Artero
Journal:  World J Transplant       Date:  2022-01-18

7.  High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach.

Authors:  Isabel Solares; Laura Izquierdo-Sánchez; Montserrat Morales-Conejo; Daniel Jericó; Francisco Javier Castelbón; Karol Marcela Córdoba; Ana Sampedro; Carlos Lumbreras; María Jesús Moreno-Aliaga; Rafael Enríquez de Salamanca; Pedro Berraondo; Antonio Fontanellas
Journal:  Biomedicines       Date:  2021-03-05

Review 8.  Mechanisms of Neuronal Damage in Acute Hepatic Porphyrias.

Authors:  Andrea Ricci; Elena Di Pierro; Matteo Marcacci; Paolo Ventura
Journal:  Diagnostics (Basel)       Date:  2021-11-26

Review 9.  Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution.

Authors:  Miriam Longo; Erika Paolini; Marica Meroni; Paola Dongiovanni
Journal:  Biomedicines       Date:  2022-03-11

10.  Evaluation of Metabolic Changes in Acute Intermittent Porphyria Patients by Targeted Metabolomics.

Authors:  Alex Gomez-Gomez; Paula Aguilera; Klaus Langohr; Gregori Casals; Cristina Pavon; Josep Marcos; Jordi To-Figueras; Oscar J Pozo
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.